DRUG TRANSPORTERS IN THE INTESTINE - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 513

pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc
Natl Acad SciUSA94(8):4028-4033.
45. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P,
Nooijen WJ, Beijnen JH, van Tellingen O. 1997. Limited oral bioavailability and active
epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc
Natl Acad SciUSA94(5):2031-2035.
46. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. 2003. P-
Glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol
Ther 73(3):223-231.
47. Lin JH. 2004. How significant is the role of P-glycoprotein in drug absorption and brain
uptake? Drugs Today (Barc) 40(1):5-22.
48. Benet LZ, Cummins CL, Wu CY. 2004. Unmasking the dynamic interplay between efflux
transporters and metabolic enzymes. Int J Pharm 277(1-2):3-9.
49. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. 1998. A
multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad
SciUSA95(26):15665-15670.
50. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger
L, Dean M, Fojo T, Bates SE. 1999. Molecular cloning of cDNAs which are highly over-
expressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport
genes. Cancer Res 59(1):8-13.
51. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. 1998. A human
placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved
in multidrug resistance. Cancer Res 58(23):5337-5339.
52. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, Sugimoto Y. 2002.
Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump
through the inhibition of S-S dependent homodimerization. Int J Cancer 97(5):626-
630.
53. Nakanishi T, Doyle LA, Hassel B, Wei Y, Bauer KS, Wu S, Pumplin DW, Fang HB, Ross
DD. 2003. Functional characterization of human breast cancer resistance protein (BCRP,
ABCG2) expressed in the oocytes of Xenopus laevis . Mol Pharmacol 64(6):1452-1462.
54. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. 2004. Characterization of oligomeric human
half-ABC transporter ATP-binding cassette G2. J Biol Chem 279(19):19781-19789.
55. Jonker JW, Buitelaar M, Wagenaar E, van der Valk MA, Scheffer GL, Scheper RJ, Plosch
T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel. AH 2002. The breast cancer
resistance protein protects against a major chlorophyll-derived dietary phototoxin and
protoporphyria. Proc Natl Acad SciUSA99(24):15649-15654.
56. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH.
2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration
of topotecan. J Natl Cancer Inst 92(20):1651-1656.
57. Kruijtzer CM, Beijnen JH, Rosing H, Bokkel Huinink WW, Schot M, Jewell RC, Paul
EM, Schellens JH. 2002. Increased oral bioavailability of topotecan in combination with
the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol
20(13):2943-2950.
58. Rosing H, van Zomeren DM, Doyle E, Bult A, Beijnen JH. 1998. O-glucuronidation, a
newly identified metabolic pathway for topotecan and N -desmethyl topotecan. Anticancer
Drugs 9(7):587-592.